What's in Instituto Bernabeu's pipeline?

Instituto Bernabeu has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Instituto Bernabeu's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/instituto-bernabeu.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Instituto Bernabeu — Portfolio Competitive Intelligence Brief

Instituto Bernabeu pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Urinary Human follicle stimulating hormone	Urinary Human follicle stimulating hormone	marketed
Progesterone 200 MG	Progesterone 200 MG	marketed
Gonadotrophins	Gonadotrophins	marketed	Other

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Instituto Bernabeu:

Cite this brief

Drug Landscape (2026). Instituto Bernabeu — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-bernabeu. Accessed 2026-05-14.